Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview
-
Published:2024-07-29
Issue:Suppl. 2
Volume:11
Page:1-4
-
ISSN:2283-5733
-
Container-title:Global and Regional Health Technology Assessment
-
language:
-
Short-container-title:Grhta
Publisher
Aboutscience Srl
Reference35 articles.
1. Tang KWK, Millar BC, Moore JE. Antimicrobial resistance (AMR). Br J Biomed Sci. 2023;80:11387. https://doi.org/10.3389/bjbs.2023.11387 PMID:37448857
2. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. https://doi.org/10.1111/j.1469-0691.2011.03570.x PMID:21793988
3. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35(10)(suppl 2):S165-S193. https://doi.org/10.1016/j.ajic.2007.10.006 PMID:18068814
4. Ancillotti M, Nihlén Fahlquist J, Eriksson S. Individual moral responsibility for antibiotic resistance. Bioethics. 2022;36(1):3-9. https://doi.org/10.1111/bioe.12958 PMID:34599841
5. Glasner C, Berends MS, Becker K, et al. A prospective multicentre screening study on multidrug-resistant organisms in intensive care units in the Dutch-German cross-border region, 2017 to 2018: the importance of healthcare structures. Euro Surveill. 2022;27(5):1. https://doi.org/10.2807/1560-7917.ES.2022.27.5.2001660 PMID:35115078